Evidence map›Paper›PMID 28119472›Full record

ArticlemBio2017

Pseudomonas aeruginosa Pore-Forming Exolysin and Type IV Pili Cooperate To Induce Host Cell Lysis.

Pauline Basso, Michel Ragno, Sylvie Elsen, Emeline Reboud, Guillaume Golovkine, Stephanie Bouillot, Philippe Huber, Stephen Lory, Eric Faudry, Ina Attrée

Open access · goldAbstract read
In one paragraph

Article in mBio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. AvirulentmicroLife · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Cells · 2023
    Review
  15. Article
  16. Article
  17. Article
  18. ExlA: A New Contributor toFrontiers in cellular and infection microbiology · 2022
    Review
  19. Virulence Factors ofFrontiers in cellular and infection microbiology · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Pauline BassoUniversity of Grenoble Alpes, Grenoble, France.
Michel RagnoUniversity of Grenoble Alpes, Grenoble, France.
Sylvie ElsenUniversity of Grenoble Alpes, Grenoble, France.
Emeline ReboudUniversity of Grenoble Alpes, Grenoble, France.
Guillaume GolovkineUniversity of Grenoble Alpes, Grenoble, France.
Stephanie BouillotUniversity of Grenoble Alpes, Grenoble, France.
Philippe HuberUniversity of Grenoble Alpes, Grenoble, France.
Stephen LoryDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA.
Eric FaudryUniversity of Grenoble Alpes, Grenoble, France.
Ina AttréeUniversity of Grenoble Alpes, Grenoble, France ina.attree-delic@cea.fr.
Commissariat à l'Énergie Atomique et aux Énergies Alternatives · FRUniversité Grenoble Alpes · FRCEA Grenoble · FRCentre National de la Recherche Scientifique · FRHarvard University · USInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical strains of Pseudomonas aeruginosa lacking the type III secretion system genes employ a toxin, exolysin (ExlA), for host cell membrane disruption. Here, we demonstrated that ExlA export requires a predicted outer membrane protein, ExlB, showing that ExlA and ExlB define a new active two-partner secretion (TPS) system of P. aeruginosa In addition to the TPS signals, ExlA harbors several distinct domains, which include one hemagglutinin domain, five arginine-glycine-aspartic acid (RGD) motifs, and a C-terminal region lacking any identifiable sequence motifs. However, this C-terminal region is important for the toxic activity, since its deletion abolishes host cell lysis. Using lipid vesicles and eukaryotic cells, including red blood cells, we demonstrated that ExlA has a pore-forming activity which precedes cell membrane disruption of nucleated cells. Finally, we developed a high-throughput cell-based live-dead assay and used it to screen a transposon mutant library of an ExlA-producing P. aeruginosa clinical strain for bacterial factors required for ExlA-mediated toxicity. The screen resulted in the identification of proteins involved in the formation of type IV pili as being required for ExlA to exert its cytotoxic activity by promoting close contact between bacteria and the host cell. These findings represent the first example of cooperation between a pore-forming toxin of the TPS family and surface appendages in host cell intoxication. IMPORTANCE: The course and outcome of acute, toxigenic infections by Pseudomonas aeruginosa clinical isolates rely on the deployment of one of two virulence strategies: delivery of effectors by the well-known type III secretion system or the cytolytic activity of the recently identified two-partner secreted toxin, exolysin. Here, we characterize several features of the mammalian cell intoxication process mediated by exolysin. We found that exolysin requires the outer membrane protein ExlB for export into extracellular medium. Using in vitro recombinant protein and ex vivo assays, we demonstrated a pore-forming activity of exolysin. A cellular cytotoxicity screen of a transposon mutant library, made in an exolysin-producing clinical strain, identified type IV pili as bacterial appendages required for exolysin toxic function. This work deciphers molecular mechanisms underlying the activity of novel virulence factors used by P. aeruginosa clinical strains lacking the type III secretion system, including a requirement for the toxin-producing bacteria to be attached to the targeted cell to induce cytolysis, and defines new targets for developing antivirulence strategies.

Indexed as

Cell SurvivalDNA Transposable ElementsFimbriae, BacterialMutagenesis, InsertionalPore Forming Cytotoxic ProteinsPseudomonas aeruginosaType II Secretion SystemsDNA Transposable ElementsPore Forming Cytotoxic ProteinsType II Secretion Systems

Identifiers

PMID28119472
PMCPMC5263249
OpenAlexW2582033886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.